Sunday, August 14, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Funding for the next pandemic

by Medical Finance
in Coronavirus
Surveying communities may be a useful tool for predicting COVID-19 case trajectories
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

President Joe Biden released his budget proposal for 2023 this week, and it calls for a nearly 27% increase in funding for the Department of Health and Human Services. That includes $28 billion for the Centers for Disease Control and Prevention to implement a preparedness program for future pandemics and $40 billion for HHS to invest in making vaccines and other medicines.

Also, the FDA and the CDC authorized a second booster shot for most people 50 and older. But federal officials offered little advice to consumers about who might need that shot and when.

This week’s panelists are Mary Agnes Carey of KHN, Amy Goldstein of The Washington Post, Jennifer Haberkorn of the Los Angeles Times, and Rachana Pradhan of KHN.

Among the takeaways from this week’s episode:

  • Biden’s advocacy for funding preparations for a future pandemic reinforces his sense of urgency in bolstering the public health infrastructure, but whether Congress will take that track is unknown. Already, some lawmakers are balking at the administration’s request for more money to help fund additional covid-19 testing and vaccine efforts.
  • A bipartisan group of senators has been meeting in the past several days hoping to find a compromise to restore funding for testing and vaccinations. Republicans have complained that earlier appropriations for covid have been spent too recklessly and that there isn’t enough transparency about where it has gone. They would like some of the funds that haven’t been spent to be clawed back. There is no indication yet that the group of senators has a plan for moving forward, but the upcoming spring recess for Easter and Passover may provide a deadline that helps focus the debate.
  • The administration originally sought more than $20 billion for testing and vaccines. Congress appeared ready to spend about $15 billion before hitting the impasse. Some reports suggest that the Senate negotiators are talking about $10 billion, which may provide funding for only several months.
  • The Centers for Medicare & Medicaid Services also announced this week that a new analysis shows the growth in health spending in the U.S. has slowed.
  • Millions of Americans are expected to lose Medicaid coverage once the covid emergency ends and states will be able to disenroll people who no longer meet eligibility requirements. Advocates warn that some of those people will not move to other coverage options, such as insurance offered on the Affordable Care Act’s insurance marketplaces.
  • One priority of the ACA was to help drive down health costs, and the law established an innovation center to fund projects looking for ways to do that. Experts at the time suggested that value-based care could make a difference, and the center has made that a guiding principle in its research. But there is little evidence so far that such efforts are producing meaningful results.

Also this week, Julie Rovner interviews KHN’s Julie Appleby, who reported and wrote the latest KHN-NPR “Bill of the Month” installment about a very expensive air ambulance ride. If you have an outrageous medical bill you’d like to share with us, you can do that here.

Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too:

Mary Agnes Carey: The New Yorker’s “A Freelancer’s Forty-Three Years in the American Health-Care System,” by David Owen

Amy Goldstein: Stat’s “NIH’s Identity Crisis: The Pandemic and The Search for a New Leader Leave the Agency at a Crossroads,” by Lev Facher

Jennifer Haberkorn: The New York Times’ “F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?” by Christina Jewett

Rachana Pradhan: The Washington Post’s “’Is This What a Good Mother Looks Like?'” by William Wan

Also discussed on this week’s podcast:

The Wall Street Journal’s “You Likely Don’t Need a Fourth Covid Shot,” by Philip Krause and Luciana Borio


To hear all our podcasts, click here.

And subscribe to KHN’s What the Health? on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts.




Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Site Density Functional Theory and Structural Bioinformatics Analysis of the SARS-CoV Spike Protein and hACE2 Complex. Image Credit: Juan Gaertner/Shutterstock

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

by Medical Finance
August 14, 2022
0

The coronavirus disease 2019 (COVID-19) pandemic disrupted the normal functioning of society, business, and education while taking a grievous...

Study: COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins. Image Credit: createiveneko / Shutterstock.com

COVID-19 vaccines elicit cross-reactive antibodies against endemic coronaviruses

by Medical Finance
August 14, 2022
0

In a recent study published on the medRxiv* preprint server, researchers study the interaction between immunity to endemic coronaviruses (CoVs)...

Study: Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Image Credit: DOERS / Shutterstock.com

Escape from vaccine-induced immunity likely contributed to rapid rise of SARS-CoV-2 Omicron

by Medical Finance
August 14, 2022
0

In a recent study published on the medRxiv* preprint server, researchers investigate whether the severe acute respiratory syndrome coronavirus 2...

Study: mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children. Image Credit: rafapress / Shutterstock.com

Children and adolescents respond as well or better than adults to mRNA-1273 COVID vaccination

by Medical Finance
August 14, 2022
0

A recent study published on the medRxiv* preprint server assesses the neutralization efficacy of the Moderna mRNA-1273 vaccine against the...

Study: Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipients. Image Credit: Wetzkaz Graphics / Shutterstock.com

Study shows homologous COVID boosters better than heterologous in most kidney transplant recipients

by Medical Finance
August 14, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers screen kidney transplant recipients to evaluate their serological responses following...

Study: Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Image Credit: GEMINI PRO STUDIO / Shutterstock.com

Immunity based upon “mild” Omicron infection is weak for Omicron reinfection

by Medical Finance
August 14, 2022
0

In a recent study published on the medRxiv* preprint server, an interdisciplinary team of researchers from the United States evaluate...

Next Post
Review: From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

Study: Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. Image Credit: MedMoMedia / Shutterstock.com

SARS-CoV-2 Omicron a product of offensive evolution with compromised antigenicity

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Image Credit: NIKCOA / Shutterstock.com
    A dangerous or beneficial plant?
  • An example of the life cycle of a virus.
    Advancing virus research with specialized tools
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply